Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OncoPep, Inc.
Derived from Strategic Transactions, a premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2014.
START-UP’s monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical devices.
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
Sleep is getting a lot of attention in the clinical community these days, and in particular, interrupted sleep. The obstructive sleep apnea market for treatment, monitoring and diagnostic products is forecast to grow at an almost 13% compound annual growth rate through the year 2010 based on only incremental changes to existing diagnostic and treatment modalities, according to "US Markets for Blood Gas/Electrolyte Monitoring, Pulmonary Function Assessment, and Sleep Apnea Management Products," published in December 2005 by Medtech Insight. But the field is beginning to see an influx of new kinds of treatments from both the medical device and pharmaceutical industries as well.
- Large Molecule